Syngene International Ltd
NSE:SYNGENE

Watchlist Manager
Syngene International Ltd Logo
Syngene International Ltd
NSE:SYNGENE
Watchlist
Price: 847.2 INR 0.55%
Market Cap: 340B INR
Have any thoughts about
Syngene International Ltd?
Write Note

Syngene International Ltd
Tax Provision

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Syngene International Ltd
Tax Provision Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Tax Provision CAGR 3Y CAGR 5Y CAGR 10Y
Syngene International Ltd
NSE:SYNGENE
Tax Provision
-â‚ą1B
CAGR 3-Years
-10%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Divi's Laboratories Ltd
NSE:DIVISLAB
Tax Provision
-â‚ą6B
CAGR 3-Years
8%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
Suven Life Sciences Ltd
NSE:SUVEN
Tax Provision
â‚ą10m
CAGR 3-Years
-19%
CAGR 5-Years
-44%
CAGR 10-Years
N/A
Dishman Carbogen Amcis Ltd
NSE:DCAL
Tax Provision
-â‚ą231m
CAGR 3-Years
44%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Vimta Labs Ltd
NSE:VIMTALABS
Tax Provision
-â‚ą136.1m
CAGR 3-Years
-9%
CAGR 5-Years
-10%
CAGR 10-Years
-12%
I
Innova Captab Ltd
NSE:INNOVACAP
Tax Provision
-â‚ą351.8m
CAGR 3-Years
-44%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Syngene International Ltd
Glance View

Market Cap
339.9B INR
Industry
Life Sciences Tools & Services

In the bustling landscape of the global pharmaceutical industry, Syngene International Ltd. stands out as a beacon of scientific innovation and strategic acumen. Founded in 1993, this Bangalore-based contract research and manufacturing organization (CRMO) has carved a niche by seamlessly blending cutting-edge research with commercial savvy. Syngene offers integrated services spanning the entire drug discovery and development continuum, catering to diverse sectors including pharmaceuticals, biotechnology, nutrition, animal health, consumer goods, and specialty chemicals. By providing end-to-end solutions, from target identification and discovery chemistry to pre-clinical and clinical development and up to commercial manufacturing, Syngene ensures that its clients can focus on their core competencies, thus accelerating their journey from lab to market. Syngene's revenue model thrives on fostering long-term partnerships with global giants such as Bristol-Myers Squibb, Amgen, and Baxter, who rely on the company's deep scientific expertise and robust infrastructure. By offering bespoke solutions that address specific client needs, Syngene generates income through flexible, multi-year contracts and milestone payments at various stages of the drug development cycle. This approach not only ensures a steady revenue stream but also strengthens Syngene's reputation as a trusted partner in scientific innovation. With their state-of-the-art facilities and a team of world-class scientists, Syngene effectively marries scientific curiosity with business excellence, driving the future of health sciences and securing its position as a pivotal player in the CRMO field.

SYNGENE Intrinsic Value
610.52 INR
Overvaluation 28%
Intrinsic Value
Price

See Also

What is Syngene International Ltd's Tax Provision?
Tax Provision
-1B INR

Based on the financial report for Sep 30, 2024, Syngene International Ltd's Tax Provision amounts to -1B INR.

What is Syngene International Ltd's Tax Provision growth rate?
Tax Provision CAGR 5Y
0%

Over the last year, the Tax Provision growth was 29%. The average annual Tax Provision growth rates for Syngene International Ltd have been -10% over the past three years .

Back to Top